In:
Oncology, S. Karger AG, Vol. 77, No. 5 ( 2009), p. 300-303
Abstract:
〈 i 〉 Objectives: 〈 /i 〉 We performed a pilot study of a modified combination chemotherapy regimen with S-1 plus gemcitabine for patients with advanced pancreatic cancer. 〈 i 〉 Methods: 〈 /i 〉 Gemcitabine was administered at a dose of 1,000 mg/m 〈 sup 〉 2 〈 /sup 〉 in a 30-min intravenous injection on days 1 and 15. S-1 was administered orally at a dose of 40 mg/m 〈 sup 〉 2 〈 /sup 〉 twice daily for 14 consecutive days followed by a 14-day rest. Each cycle was repeated every 28 days. 〈 i 〉 Results: 〈 /i 〉 Sixteen patients were enrolled. No complete response was observed and partial response was observed in 5 patients (31.3%), stable disease in 10 patients (62.5%) and progressive disease in 1 patient (6.3%). The median time to progression was 10.0 months (95% CI 4.4–N.A.) and the median survival time was 20.4 months (95% CI 8.6–24.1 months). The major toxicities were grade 3 neutropenia (25.0%) and grade 3 anemia (6.3%). There were no grade 4 toxicities. 〈 i 〉 Conclusions: 〈 /i 〉 Combination therapy with gemcitabine and S-1 using the modified 4-week schedule was well tolerated and efficacious for advanced pancreatic cancer.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2009
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink